• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

前瞻性纵向队列研究 COVID-19 患者及其家庭成员的方案，以研究与疾病严重程度相关的因素：PreCOVID 研究。

Protocol for a prospective, longitudinal cohort of people with COVID-19 and their household members to study factors associated with disease severity: the Predi-COVID study.

机构信息

Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg.

IBBL, Luxembourg, Luxembourg.

出版信息

BMJ Open. 2020 Nov 23;10(11):e041834. doi: 10.1136/bmjopen-2020-041834.

DOI:10.1136/bmjopen-2020-041834
PMID:33234656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7684799/
Abstract

INTRODUCTION

A few major clinical factors such as sex, obesity or comorbidities have already been associated with COVID-19 severity, but there is a need to identify new epidemiological, clinical, digital and biological characteristics associated with severity and perform deep phenotyping of patients according to severity. The objectives of the Predi-COVID study are (1) to identify new determinants of COVID-19 severity and (2) to conduct deep phenotyping of patients by stratifying them according to risk of complications, as well as risk factors for infection among household members of Predi-COVID participants (the Predi-COVID-H ancillary study).

METHODS AND ANALYSIS

Predi-COVID is a prospective, hybrid cohort study composed of laboratory-confirmed COVID-19 cases in Luxembourg who will be followed up remotely for 1 year to monitor their health status and symptoms. Predi-COVID-H is an ancillary cohort study on household members of index cases included in Predi-COVID to monitor symptoms and household clusters in this high-risk population. A subcohort of up to 200 Predi-COVID and 300 Predi-COVID-H participants with biological samples will be included. Severity of infection will be evaluated by occurrence and duration of hospitalisation, admission and duration of stay in intensive care units or equivalent structures, provision of and duration of supplemental oxygen and ventilation therapy, transfer to another hospital, as well as the impact of infection on daily activities following hospital discharge.

ETHICS AND DISSEMINATION

The study has been approved by the National Research Ethics Committee of Luxembourg (study number 202003/07) in April 2020. An informed consent is signed by study participants. Scientific articles will be submitted to international peer-reviewed journals, along with press releases for lay audience for major results.

TRIAL REGISTRATION NUMBER

NCT04380987.

摘要

简介

一些主要的临床因素，如性别、肥胖或合并症，已经与 COVID-19 的严重程度相关，但仍需要确定与严重程度相关的新的流行病学、临床、数字和生物学特征，并根据严重程度对患者进行深度表型分析。Predi-COVID 研究的目的是（1）确定 COVID-19 严重程度的新决定因素，（2）通过对参与者的家庭成员中的感染危险因素进行分层，根据并发症风险对患者进行深度表型分析（Predi-COVID-H 辅助研究）。

方法和分析

Predi-COVID 是一项前瞻性的混合队列研究，包括卢森堡确诊的 COVID-19 病例，这些病例将通过远程随访 1 年，监测其健康状况和症状。Predi-COVID-H 是对 Predi-COVID 中纳入的指数病例的家庭成员进行的辅助队列研究，以监测这一高危人群的症状和家庭聚集情况。将纳入最多 200 名 Predi-COVID 和 300 名 Predi-COVID-H 有生物样本的参与者。感染严重程度将通过住院、入住和入住重症监护病房或同等结构的时间、补充氧气和通气治疗的提供和持续时间、转院以及感染对出院后日常生活的影响来评估。

伦理和传播

该研究已于 2020 年 4 月获得卢森堡国家研究伦理委员会的批准（研究编号 202003/07）。研究参与者签署了知情同意书。科学文章将提交给国际同行评议期刊，并向广大受众发布主要结果的新闻稿。

试验注册号

NCT04380987。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/1fa612dfe4a2/bmjopen-2020-041834f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/e75fa1acb181/bmjopen-2020-041834f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/b2adad6a60a5/bmjopen-2020-041834f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/1fa612dfe4a2/bmjopen-2020-041834f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/e75fa1acb181/bmjopen-2020-041834f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/b2adad6a60a5/bmjopen-2020-041834f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2294/7684799/1fa612dfe4a2/bmjopen-2020-041834f03.jpg

相似文献

1
Protocol for a prospective, longitudinal cohort of people with COVID-19 and their household members to study factors associated with disease severity: the Predi-COVID study.前瞻性纵向队列研究 COVID-19 患者及其家庭成员的方案，以研究与疾病严重程度相关的因素：PreCOVID 研究。
BMJ Open. 2020 Nov 23;10(11):e041834. doi: 10.1136/bmjopen-2020-041834.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: results from the prospective Predi-COVID cohort study.感染前体力活动与 COVID-19 疾病严重程度和症状的关联：前瞻性 PreDi-COVID 队列研究结果。
BMJ Open. 2022 Apr 29;12(4):e057863. doi: 10.1136/bmjopen-2021-057863.
4
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).老年人伴有症状的严重急性呼吸综合征冠状病毒 2 型感染（COVID-19）的家庭治疗：一项多臂多阶段（MAMS）随机试验研究方案的结构化总结，旨在评估几种实验性治疗方法在降低 65 岁及以上门诊患者住院或死亡风险方面的疗效和耐受性（COVERAGE 试验）。
Trials. 2020 Oct 13;21(1):846. doi: 10.1186/s13063-020-04619-1.
5
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
6
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益（CoV-Surv 研究）：一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
7
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病（NO COVID-19）实用开放性标签研究，评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
8
A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".一项评估使用 gammaCore®-Sapphire 设备进行迷走神经刺激治疗中度至重度 CoViD-19 呼吸症状的前瞻性、随机、对照研究（SAVIOR）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 26;21(1):576. doi: 10.1186/s13063-020-04486-w.
9
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.皮下注射沙利鲁单抗治疗中重度 COVID-19 感染住院患者与标准治疗（SARCOVID）的比较：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 9;21(1):772. doi: 10.1186/s13063-020-04588-5.
10
Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.轻症肺炎患者无需住院的情况下使用类固醇进行 COVID-19 门诊治疗作为改变疾病进程的机会：一项随机对照试验的结构化总结。
Trials. 2020 Jul 9;21(1):632. doi: 10.1186/s13063-020-04575-w.

引用本文的文献

1
Trajectories of persisting Covid- 19 symptoms up to 24 months after acute infection: findings from the Predi-Covid cohort study.急性感染后长达24个月的持续性新冠症状轨迹：Predi-Covid队列研究的结果
BMC Infect Dis. 2025 Apr 25;25(1):603. doi: 10.1186/s12879-025-11023-0.
2
Association of LEF1-AS1 with cardiovascular and neurological complications of COVID-19.LEF1-AS1与新型冠状病毒肺炎心血管及神经并发症的关联
J Mol Cell Cardiol Plus. 2024 Dec 22;11:100280. doi: 10.1016/j.jmccpl.2024.100280. eCollection 2025 Mar.
3
Co-design of a voice-based app to monitor long COVID symptoms with its end-users: A mixed-method study.

本文引用的文献

1
Duty to Plan: Health Care, Crisis Standards of Care, and Novel Coronavirus SARS-CoV-2.规划职责：医疗保健、危机护理标准与新型冠状病毒SARS-CoV-2
NAM Perspect. 2020 Mar 5;2020. doi: 10.31478/202003b. eCollection 2020.
2
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
3
Covid-19: Concerns rise as cases expand rapidly in South America.新冠疫情：随着南美洲病例迅速增加，担忧情绪上升。
与最终用户共同设计一款基于语音的应用程序以监测新冠长期症状：一项混合方法研究。
Digit Health. 2024 Sep 9;10:20552076241272671. doi: 10.1177/20552076241272671. eCollection 2024 Jan-Dec.
4
Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality.基于长链非编码 RNA 的机器学习模型预测 COVID-19 住院患者死亡率的建立。
Nat Commun. 2024 May 20;15(1):4259. doi: 10.1038/s41467-024-47557-1.
5
Firalink: A bioinformatics pipeline for long non-coding RNA data analysis.Firalink：一种用于长链非编码RNA数据分析的生物信息学流程。
Noncoding RNA Res. 2023 Sep 12;8(4):602-604. doi: 10.1016/j.ncrna.2023.09.002. eCollection 2023 Dec.
6
Co-Design of a Voice-Based Digital Health Solution to Monitor Persisting Symptoms Related to COVID-19 (UpcomingVoice Study): Protocol for a Mixed Methods Study.基于语音的数字健康解决方案与新冠病毒相关持续症状监测的协同设计（即将开展的语音研究）：一项混合方法研究的方案
JMIR Res Protoc. 2023 Jun 19;12:e46103. doi: 10.2196/46103.
7
Association between use of psychotropic medications prior to SARS-COV-2 infection and trajectories of COVID-19 recovery: Findings from the prospective Predi-COVID cohort study.感染 SARS-CoV-2 之前使用精神药物与 COVID-19 恢复轨迹的关系：前瞻性 Predi-COVID 队列研究的结果。
Front Public Health. 2023 Mar 16;11:1055440. doi: 10.3389/fpubh.2023.1055440. eCollection 2023.
8
Altered infective competence of the human gut microbiome in COVID-19.COVID-19 中人类肠道微生物组感染能力的改变。
Microbiome. 2023 Mar 9;11(1):46. doi: 10.1186/s40168-023-01472-7.
9
A voice-based biomarker for monitoring symptom resolution in adults with COVID-19: Findings from the prospective Predi-COVID cohort study.一种用于监测新冠肺炎成年患者症状缓解的基于语音的生物标志物：前瞻性Predi-COVID队列研究的结果。
PLOS Digit Health. 2022 Oct 20;1(10):e0000112. doi: 10.1371/journal.pdig.0000112. eCollection 2022 Oct.
10
Post-acute COVID and long-COVID among adults and older adults in the State of Paraná, Brazil: protocol for an ambispective cohort study.巴西帕拉纳州成年人和老年人的新冠后和长新冠：一项前瞻性队列研究方案。
BMJ Open. 2022 Sep 8;12(9):e061094. doi: 10.1136/bmjopen-2022-061094.
BMJ. 2020 May 13;369:m1926. doi: 10.1136/bmj.m1926.
4
Covid-19: Death rate in England and Wales reaches record high because of covid-19.新冠疫情：英格兰和威尔士因新冠疫情死亡率创历史新高。
BMJ. 2020 Apr 14;369:m1484. doi: 10.1136/bmj.m1484.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
6
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.